December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.690 -0.210 (-4.29%)
Streaming Delayed Price Updated: 9:42 AM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
Why AtaiBeckley Stock Surged Today ↗
President Trump wants to fast-track psychedelic research. 
Via The Motley Fool
Topics Government
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
Via MarketBeat
News headline image
AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating ↗
AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews. 
Via Benzinga
Topics Government
What's going on in today's session ↗
Via Chartmill
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Jefferies sees restrictions around non-recreational psychedelics eventually loosen up. 
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
Analyst Expectations For ATAI Life Sciences's Future ↗
 
Via Benzinga
News headline image
Why Atai Life Sciences Stock Was So Lively This Week ↗
The company, which focuses on psychedelic-based medicine, had a busy few days on both the regulatory and financing fronts. 
Via The Motley Fool
News headline image
Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides
As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside ↗
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035. 
Via Benzinga
News headline image
Alibaba, Lithium Americas And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Why Atai Life Sciences Stock Crushed It on Tuesday ↗
Investors cheered good news from the lab delivered by the company. 
Via The Motley Fool
News headline image
Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients ↗
Atai Life Sciences and Beckley Psytech report strong BPL-003 study results in treatment-resistant depression, with Phase 3 trials expected in 2026. 
Via Benzinga
News headline image
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% ↗
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA), 
Via Benzinga
Topics Artificial Intelligence
News headline image
Atai Life Sciences Revenue Jumps 163% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Why Is ATAI Life Sciences Stock Trading Lower On Monday? ↗
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile. 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Higher As US-EU Ink Trade Deal: Tesla, Palantir, UnitedHealth In Focus ↗
U.S. stock futures rose on Monday after ending higher on Friday. Futures of major benchmark indices were higher. 
Via Benzinga
News headline image
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.